Hero image

Clinical studies

“Clinical studies are the key to gaining new knowledge about the diagnosis and treatment of diseases. We’re proud to be contributing to this effort in Switzerland.”

Klaudia Georgi, Director Clinical Research MSD Switzerland & Austria

Our work by the numbers

34

ongoing clinical studies in Switzerland (as of 11/2021)

15

first-in-class medicines approved in Switzerland since 2000 (as of 11/2021)

95

million Swiss francs invested in research since 2012 (as of 11/2021)

MSD Switzerland's clinical research is coordinated at our site in the Citybay building in Lucerne

MSD's clinical study program in Switzerland (as of 11/2021)

(published on www.clinicaltrials.gov)

In the field of Infectiology

HIV

MK-8591A-017 – recruitment closed
A Phase 3 Randomized, Active-Controlled, Open-Label Clinical Study to Evaluate a Switch to MK-8591A Once-Daily in Participants With HIV-1 Virologically Suppressed on Antiretroviral Therapy

Study center: Basel, Bern, Geneva, Lugano, St. Gallen, Zurich

 

MK-8591-013 – recruitment closed
A Phase 2b, Randomized, Active-Controlled, Double-Blind, Dose-Ranging Clinical Study to Evaluate a Switch to Islatravir (ISL) and MK-8507 Once-Weekly in Adults with HIV-1 Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) Once Daily

Study center: Basel, Bern, Geneva, Lausanne, Zurich

 

MK-8591A-033 – study in start up
A Phase 3 Open-label Rollover Clinical Study of Doravirine/Islatravir (DOR/ISL) Once-daily for the Treatment of HIV-1 Infection in Participants Who Previously Received DOR/ISL in a Phase 2 or Phase 3 DOR/ISL Clinical Study

Study center: Basel, Bern, Geneva, Lugano, St. Gallen, Zurich


In the field of Oncology

Bladder Cancer

MK-3475-676/KEYNOTE-676 – still recruiting
A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Bacillus Calmette-Guerin (BCG) in Participants with High-risk Non-muscle Invasive Bladder Cancer (HRNMIBC) that is Persistent or Recurrent Following BCG Induction (KEYNOTE-676)

Study center: Basel, Geneva, Zurich


Blood Cancer (Hematologic Malignancies)

MK-1026-003 – study in start up
A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants with Hematologic Malignancies

Study center: Bellinzona, Bern, Zurich


Colorectal Cancer

MK-3475-177/KEYNOTE-177 – recruitment closed
A Phase III Study of Pembrolizumab (MK-3475) vs. Chemotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma

Study center: Geneva, Zurich


Head and Neck Cancer

MK-3475-040/KEYNOTE-040 – study will be closed shortly
A Phase III Randomized Trial of MK-3475 (Pembrolizumab) versus Standard Treatment in Subjects with Recurrent or Metastatic Head and Neck Cancer

Study center: Geneva, Lucerne

 

MK-3475-048/KEYNOTE-048 – study will be closed shortly
A Phase 3 Clinical Trial of Pembrolizumab (MK-3475) in First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Study center: Zurich, Lausanne

 

MK-3475-689/KEYNOTE-689 – still recruiting
A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)

Study center: Bellinzona, Geneva, Zurich


Hepatocellular Cancer

MK-1308A-004 – still recruiting
A Phase 2, Multicenter, Clinical Study to Evaluate the Safety and Efficacy of MK 1308A (Coformulated MK 1308/MK 3475) in Combination with Lenvatinib (E7080/MK 7902) in First-line Therapy of Participants with Advanced Hepatocellular

Study center: Bern, Geneva, Lausanne, St. Gallen, Zurich


Kidney Cancer (Renal Cell Carcinoma)

MK-6482-011 – still recruiting
An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Second-line or Third-line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 Therapy

Study center: Bellinzona, Chur, Geneva, Zurich


Liver Cancer

MK-3475-937/KEYNOTE-937 – still recruiting
A phase III adjuvant, randomized, placebo – controlled, double-blinded study, in surgically resected or ablated HCC patients

Study center: Basel, Bern, Geneva, Lausanne, St. Gallen, Winterthur, Zurich


Lung Cancer

MK-3475-042/KEYNOTE-042 – study will be closed shortly
A Randomized, Open Label, Phase III Study of Overall Survival Comparing Pembrolizumab (MK-3475) Versus Platinum Based Chemotherapy in Treatment Naïve Subjects With PD-L1 Positive Advanced or Metastatic Non-Small Cell Lung Cancer

Study center: Basel, Bern

 

MK-3475-091/KEYNOTE-091 – outsourced
A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy (PEARLS)

Study center: Basel, Bellinzona, Bern, Chur, Geneva, Lausanne, Lucerne, St. Gallen, Winterthur, Zurich

 

MK-3475-495/KEYNOTE-495; KeyImPaCT – still recruiting
KeyImPaCT: A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab-(MK-3475, SCH 900475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer

Study center: Basel, Chur, St. Gallen, Zurich

 

MK-3475-604/KEYNOTE-604 – recruitment closed
A Phase 3 Randomized, Double-Blind, Placebo-controlled Trial of Pembrolizumab (MK-3475/SCH900475) in Combination with Etoposide/Platinum (Cisplatin or Carboplatin) for the First-line Treatment of Subjects with Extensive Stage Small Cell Lung Cancer

Study center: Chur, Lausanne

 

MK-3475-867/KEYNOTE-867 – still recruiting
A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) with or without Pembrolizumab (MK-3475) in Participants with Medically Inoperable Stages I or IIA Non Small Cell Lung Cancer (NSCLC)

Study center: Geneva, Zurich

 

MK-3475-B98 – still recruiting
A Phase 1b/2 Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination with Investigational Agents for the Treatment of Participants With PD-1/L1-refactory Extensive Stage Small Cell Lung Cancer in Need of Second-Line Therapy

Study center: St. Gallen

 

MK-3475-B99 – still recruiting
A Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab plus Investigational Agents in Combination with Etoposide and Cisplatin or Carboplatin for the First Line Treatment of Participants with Extensive Stage Small Cell Lung Cancer

Study center: St. Gallen

 

MK-7684A-002 – still recruiting
A Phase 2, Multicenter, Randomized Study to Compare the Efficacy and Safety of MK-7684A or MK-7684A Plus Docetaxel Versus Docetaxel Monotherapy in the Treatment of Participants With Metastatic Non-small Cell Lung Cancer With Progressive Disease After Treatment With a Platinum Doublet Chemotherapy and Immunotherapy

Study center: Bellinzona, Lausanne


Prostate Cancer

MK-3475-199/KEYNOTE-199 – recruitment closed
Phase II Trial of Pembrolizumab (MK-3475) in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Study center: Basel, Chur, Lucerne, St. Gallen

 

MK-3475-991 / Keynote 991 – recruitment closed
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (KEYNOTE-991)

Study center: Chur, Lausanne, St. Gallen, Zurich


Skin Cancer (Melanoma)

MK-3475-U02A – still recruiting
A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma (KEYNOTE-U02) – refractory

Study center: Lausanne, Zurich

 

MK-3475-U02B – still recruiting
A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma (KEYNOTE-U02) – 1st line

Study center: Lausanne, Zurich

 

MK-3475-U02C – still recruiting
A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma (KEYNOTE-U02) – neoadjuvant

Study center: Lausanne, Zurich

 

MK-3475-U02D – still recruiting
A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma (KEYNOTE-U02) – neoadjuvant

Study center: Lausanne, Zurich

 

MK-3475-054 / KEYNOTE-054 – outsourced
Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage III melanoma: A randomized, double-blind Phase 3 trial of the EORTC Melanoma Group

Study center: Geneva, St. Gallen, Zurich

 

MK-3475-716/KEYNOTE-716 – recruitment closed
Adjuvant Therapy with Pembrolizumab Versus Placebo in Resected High-risk Stage II Melanoma: A Randomized, Double-blind Phase 3 Study

Study center: Bellinzona, Basel, Bern, Chur, Geneva, Lausanne, Sion, St. Gallen, Zurich

 

MK-7902-003 – recruitment closed
A Phase III, Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) and Lenvatinib (E7080/MK-7902) Versus Pembrolizumab Alone as First-line Intervention in Participants with Advanced Melanoma (LEAP-003)

Study center: Chur, Zurich


Solid Tumors

MK-1084-001 – study in start up

A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and in Combination with Pembrolizumab in Subjects with KRASG12C Mutant Advanced Solid Tumors

Study center: Bellinzona, St. Gallen

 

MK-7902-005 – recruitment closed
A Multicenter, Multicenter, Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects with Selected Solid Tumors (LEAP-005)

Study center: Bellinzona, Bern, Chur, Geneva, St. Gallen, Zurich

 

MK-3475-587/KEYNOTE-587 – recruitment closed
Long-term Safety and Efficacy Extension Study for Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study

Study center: Basel, Zurich

 

MK-7339-002 – still recruiting
A Phase 2 Study of Olaparib Monotherapy in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer

Study center: Bellinzona, Geneva, Zurich


Stomach Cancer

MK-3475-859/KEYNOTE-859 – recruitment closed

A Phase III, randomized, double-blind clinical study of pembrolizumab (MK 3475) plus chemotherapy versus placebo plus chemotherapy as first line treatment in participants with previously untreated, HER2 negative, advanced gastric or gastroesophageal junction adenocarcinoma

Study center: Bellinzona, Chur, Lucerne, Zurich


Click here for an overview of Switzerland-wide studies that are seeking participants www.kofam.ch

CH-NON-00136, 11/2021